<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6072">
  <stage>Registered</stage>
  <submitdate>22/09/2015</submitdate>
  <approvaldate>22/09/2015</approvaldate>
  <nctid>NCT02558231</nctid>
  <trial_identification>
    <studytitle>The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension</studytitle>
    <scientifictitle>The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study</scientifictitle>
    <utrn />
    <trialacronym>TRITON</trialacronym>
    <secondaryid>AC-065A308</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Arterial Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Macitentan
Treatment: drugs - Tadalafil
Treatment: drugs - Selexipag

Experimental: Triple oral combination treatment - Macitentan, tadalafil, and selexipag

Placebo Comparator: Dual oral combination treatment - Macitentan, tadalafil, and placebo


Treatment: drugs: Macitentan
Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.

Treatment: drugs: Tadalafil
Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.

Treatment: drugs: Selexipag
Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pulmonary vascular resistance - As measured by right heart catheterization</outcome>
      <timepoint>Baseline to Week 26</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Signed informed consent prior to any study-mandated procedure.

          2. Male or female = 18 and = 75 years of age at screening.

          3. Initial PAH diagnosis &lt; 6 months prior to enrollment.

          4. RHC performed between Day -28 and Day 1, meeting all the following criteria:

               -  Mean pulmonary artery pressure (mPAP) = 25 mmHg.

               -  Pulmonary artery wedge pressure or left ventricular end-diastolic pressure = 15
                  mmHg.

               -  PVR = 480 dynsec/cm5 (= 6 Wood Units).

               -  Negative vasoreactivity test mandatory in idiopathic, heritable, and drug/toxin
                  induced PAH (at this or a previous RHC).

          5. Symptomatic PAH belonging to one of the following subgroups:

               -  Idiopathic.

               -  Heritable.

               -  Drug or toxin induced.

               -  Associated with one of the following: connective tissue disease; HIV infection;
                  congenital heart disease.

          6. 6-minute walk distance (6MWD) = 50 m at screening.

          7. Women of childbearing potential must not be pregnant, must perform regular pregnancy
             tests, and use reliable contraception.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Any PAH-specific drug therapy at any time.

          2. Cardio pulmonary rehabilitation program based on exercise (planned, or started = 12
             weeks prior to Day 1).

          3. Body mass index (BMI) &gt; 40 kg/m2 at screening.

          4. Presence of three or more of the following risk factors for heart failure with
             preserved ejection fraction at screening:

               -  BMI &gt; 30 kg/m2.

               -  Diabetes mellitus of any type.

               -  Essential hypertension.

               -  Coronary artery disease, i.e., any of the following:

                    -  History of stable angina or

                    -  More than 50% stenosis in a coronary artery (by coronary angiography) or

                    -  History of myocardial infarction or

                    -  History of or planned coronary artery bypass grafting and/or coronary artery
                       stenting.

          5. Acute myocardial infarction = 12 weeks prior to screening.

          6. Stroke = 12 weeks prior to screening.

          7. Known permanent atrial fibrillation.

          8. SBP &lt; 90 mmHg at screening or Day 1.

          9. Ongoing or planned treatment with organic nitrates and/or doxazosin.

         10. Presence of one or more of the following signs of relevant lung disease at any time up
             to screening:

               -  Diffusing capacity of the lung for carbon monoxide (DLCO) &lt; 40% of predicted
                  (eligible only if no or mild interstitial lung disease on computed tomography).

               -  Forced vital capacity (FVC) &lt; 60% of predicted.

               -  Forced expiratory volume in one second (FEV1) &lt; 60% of predicted.

         11. Known or suspected pulmonary veno-occlusive disease (PVOD).

         12. Documented severe hepatic impairment (with or without cirrhosis) according to National
             Cancer Institute organ dysfunction working group criteria, defined as total bilirubin
             &gt; 3 × upper limit of the normal range (ULN) accompanied by aspartate aminotransferase
             (AST) &gt; ULN (assessed by central laboratory at screening); and/or Child-Pugh Class C.

         13. Serum AST and/or alanine aminotransferase (ALT) &gt; 3 × ULN (assessed by central
             laboratory at screening).

         14. Severe renal impairment (estimated creatinine clearance = 30 mL/min/1.73 m2) assessed
             by central laboratory at screening.

         15. Ongoing or planned dialysis.

         16. Hemoglobin &lt; 100 g/L assessed by central laboratory at screening.

         17. Known or suspected uncontrolled thyroid disease (hypo- or hyperthyroidism).

         18. Loss of vision in one or both eyes because of non-arteritic ischemic optic neuropathy
             (NAION).

         19. Treatment with strong inducers of cytochrome P450 3A4 (CYP3A4; e.g., carbamazepine,
             rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's
             wort) = 28 days prior to Day 1.

         20. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole,
             voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)
             and/or strong inhibitors of CYP2C8 (e.g., gemfibrozil) = 28 days prior to Day 1.

         21. Treatment with another investigational drug (planned, or taken = 12 weeks prior to Day
             1).

         22. Hypersensitivity to any of the 3 study treatments or any excipient of their
             formulations.

         23. Pregnancy, breastfeeding, or intention to become pregnant during the study.

         24. Concomitant life-threatening disease with a life expectancy &lt; 12 months.

         25. Alcohol abuse.

         26. Any factor or condition likely to affect protocol compliance of the subject, as judged
             by the investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>238</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Albert Hospital - Camperdown, Sydney</hospital>
    <hospital>St. Vincents Hospital Sydney - Darlinghurst</hospital>
    <postcode>2050 - Camperdown, Sydney</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Kremlin-Bicêtre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Giessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Würzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Actelion</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this clinical trial is to compare the efficacy and safety of an initial
      triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral
      treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve
      patients with pulmonary arterial hypertension.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02558231</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Loic Perchenet</name>
      <address />
      <phone />
      <fax />
      <email>loic.perchenet@actelion.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>